Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

NCT06072573 is registered in ClinicalTrials.gov with Apurano Pharmaceuticals GmbH as lead sponsor.

NCT NCT06072573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06072573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Lead sponsor
Apurano Pharmaceuticals GmbH
Phase
Phase 3
Overall status
Unknown status
Start date
November 2, 2023
Completion date
December 31, 2024
Enrollment
558 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pain, chronic pain syndrome, diabetes, diabetic neuropathies, diabetic polyneuropathy, pain, pain syndrome, pain, chronic, peripheral neuralgia, peripheral neuropathy, peripheral neuropathy with type 2 diabetis